“We are very pleased that the FDA has approved the heart failure label extension of Injectafer®, and congratulate our partner on this milestone”, said Hervé Gisserot, General Manager of CSL Vifor. “Every second patient with chronic heart failure suffers from iron deficiency, with a significant number of patients either not being diagnosed or inadequately treated for iron deficiency. We are confident that Injectafer® can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients.”
Article and further references here: LINK
News: CSL CSL Ltd Says Injectafer Approved In U.S., page-2
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$282.87 |
Change
3.290(1.18%) |
Mkt cap ! $136.4B | |||
| Open | High | Low | Value | Volume |
| $281.90 | $282.89 | $281.02 | $28.08M | 99.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25 | $282.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $282.87 | 94 | 4 |
View Market Depth
| Last trade - 11.00am 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$282.73 |
Change
3.290 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| $282.06 | $282.89 | $281.58 | 7441 | ||
| Last updated 11.19am 15/05/2024 ? | |||||
| CSL (ASX) Chart |